HomeAbout UsContact Us

Cancer Research & Genetics UK

Support|Specific Cancers|Genetics|Research|News|Links

Contact Us

Email us

Charity No.

The charities registered number
is: 1121512


CRGUK is a member of the Chartered Institute of Fundraising.

Click here to find out more

Governance Code

CRGUK is committed to the Code of Fundraising Practice.

Click here to find out more


Welcome to the latest news page of our website. We shall use this page to let you know any further developments in legislature, medical information or relevant links concerning the genetics of cancer diagnosis and treatment. We shall also be updating you on the funding work carried out by the charity.

Nick Phillips - In The Press


Bowel cancer tests 'should begin ten years earlier' - click here


Cancer patient key workers: No accurate figures for Wales - click here


Some Wales cancer patients still not allocated key worker - click here


Over 50s bowel cancer tests review by Welsh government - click here


Screening 'can reduce bowel cancer risk' - click here


Calls for action on bowel cancer deaths - click here


Wales falling behind in bowel cancer screening - click here


Cancer screening rolling out too slowly - click here


Lower age for bowel cancer screening - click here

Reasearch Funding News


University of Liverpool - Ottensmeier Group

The University of Liverpool and local NHS partners recently invested in a major new programme of immunology cancer research to help translate new discoveries into novel treatments for patients as quickly as possible.

World-leading experimental cancer researcher Professor Christian Ottensmeier leads a team of interdisciplinary researchers, focusing initially on immuno-oncology in head and neck and lung cancer.

Read more - click here.


INCISE project and purchase of two high specification GPU cards

Computational workstations to enable deep learning-based bowel cancer screening in the University of Glasgow Digital Pathology Research Centre

We are delighted with the support from Cancer Research and Genetics UK which will facilitate the creation of a Digital Pathology Research Centre (DPRC) in the Institute of Cancer Sciences. As technology becomes available to improve cancer screening and diagnosis with the help of computers, we are building this centre to address this need in Glasgow and beyond. We will build on-site and remotely accessible digital workstations to further our research into cancer detection and classification with the purchase of two high specification graphics processing units (GPU) cards, connected by an interlink so they can be used together (giving a colossal 96Gb of GPU memory) or as separate cards (allowing two different scientists from two different groups to use them simultaneously). These computers are central to the deep learning aspirations of the DPRC and our first project around intestinal polyps and colorectal cancer, INCISE, which is described below.

Deep learning is used to infer conclusions from images. For example, it can examine pathology specimens and identify which cells are cancerous and whether they are actively spreading from the tumour. They can do some tasks far more accurately than a human pathologist and have the further advantage of not getting tired or bored, but we have found they are most useful when used as tools to help pathologists identify key tumour features. To do this, deep learning networks must be trained using huge amounts of data, with the amount they can hold at once determines their eventual accuracy.

Graphics processor computing is a highly specialised subfield of programming that has been embraced by the deep learning community; it is particularly suitable because the calculations that are needed to train models can be performed in parallel, making GPUs much faster than traditional computers. The computer we have requested will more than double our capacity for training new networks, which will make it possible to use more detailed and informative models. It will also be powerful enough that the computer would have been in the world's top 200 or so as recently as 2012.

We will set up an on-site (located in the Wolfson Wohl Cancer Research Centre, WWCRC) and remotely accessible well-equipped computer with two NVIDIA RTX A6000 GPU cards, linked together using an NVLINK to create a machine in which both A6000s can be used together if large, data-hungry models are needed, or separately by two groups if not.

Our exemplar project for the DPRC is the innovative INCISE (INtegrated teChnologies for Improved polyp SurveillancE) programme, which aims to transform bowel cancer screening in the UK by developing a tool that can predict which patients with precancerous growths (polyps) in their bowels, will develop further polyps in the future. Professor Joanne Edwards, Professor of Translational Cancer Pathology, is leading the collaboration consisting of academics from across the College of Medical, Veterinary and Life Sciences, NHS colleagues and Scottish technology companies. INCISE will combine polyp tissue from colorectal cancer patients with data from the NHS Greater Glasgow and Clyde Scottish Bowel Cancer Screening Programme to train algorithms to predict patients' future risks. The team will combine information about specific changes in polyp structure, as seen under the microscope and analysed using deep learning, with new analysis of the genetic mutations that cause polyps to grow. This comprehensive risk stratification tool will, for the first time, predict polyp recurrence by utilising the latest developments in digital pathology, machine learning and next generation sequencing. INCISE will improve cancer detection, whilst directly reducing the number of people requiring repeated colonoscopy, a costly, invasive, and unpleasant procedure.


Beaston Pebble Appeal

An example of the ground-breaking research taking place at Glasgow includes the work taking place in The Cagan Laboratory. They are investigating and developing new cancer treatments using a classical tool, the fruit fly, Drosophila. The fly models are designed to capture important aspects of patient tumours in a whole animal context, which are then utilised to develop unique therapies tuned to the whole-body network. Fly models have so far been developed for colorectal, thyroid, lung, and liver cancers, as well as rare inherited diseases. This innovative approach has also led to a fly-to-bedside clinical trial, towards truly personalised treatments for cancer patients.


Institute of Cancer Research

As part of their ongoing research Professor Ros Eeles' work required a centrifuge. In addition to previous donations Cancer Research Genetics UK were delighted to be able to help with a donation of £10,000. The centrifuge will help with the processing of samples and several other applications within the lab.

Professor Rosalind Eeles is searching for genetic variants that increase a person?s risk of prostate cancer and is currently leading a clinical trial looking into whether regular screening of men with certain genetic mutations leads to earlier diagnosis.

Web link - Scientists Search For Genetic Test To Spot Prostate Cancer


Chemiluminescence system for the Division of Cancer and Genetics at Cardiff University

Your generous donation will be used to purchase a chemiluminescence system for the Division of Cancer and Genetics at Cardiff University. Chemiluminescence is an analytical imaging technique that can be used to detect specific proteins in a sample using a chemical reaction to produce a white light. The system will support of the work of Professor Duncan Baird and Professor Alan Parker as well as the wider Division.

Professor Duncan Baird and his team are focused on understanding how telomere dysfunction can drive the evolution of the cancer genome. Telomeres are the structures found at the ends of chromosomes and when they become dysfunctional, they lead to large-scale genomic mutation. The lab has developed unique single-molecule approaches to determine telomere length and characterise telomere fusion events, the clinical application of these technologies has led to the development of high-resolution prognostic and predictive markers in several tumour types, including chronic lymphocytic leukaemia, multiple myeloma, myelodysplasia and breast cancer. These technologies also have applications for informing patient selection and product development of cellular therapeutics. The chemiluminescence system is essential for this research and will be used to detect specific proteins involved in DNA repair at telomeres.

Professor Alan Parker and his team research viral immunotherapies. Their research focusses on the development of refined virotherapies able to distinguish between transformed and healthy cells. Upon infection, these precision virotherapies replicate whilst simultaneously overexpressing therapeutic transgenes, typically designed to heighten the immune response against the infected cell and encoded from within the genome of the genetically modified agent. A chemiluminescence system is an essential piece of equipment and critical for the team?s day to day research.


Cancer Research & Genetics UK have donated £10,000 to the Clatterbridge Cancer Centre at the new Liverpool hospital to buy -86 C freezers for storing tissue samples of patients in cancer research. The work we are supporting will be under the guidance of Dr Maria Maguire, who is researching into the molecular mechanisms of cancer.

The Clatterbridge Cancer Centre NHS Foundation Trust is one of the UK?s leading cancer centres providing highly specialist cancer care to a population of 2.3m people across Cheshire, Merseyside and the surrounding areas including the Isle of Man.

We are a tertiary cancer centre which means we see patients who have already been diagnosed and referred to us by other hospitals. We provide non-surgical cancer care e.g. chemotherapy and radiotherapy for solid tumours and blood cancers.

Website - click here


Cancer Research & Genetics UK have donated £10k to Professor Andrew Sewell's work at Cardiff University. His research group is focused on T-cell antigens and the receptors that recognise them. Cancer Research and Genetics UK?s donation will purchase a Leica M60 Stereomicroscope and Thermo BB15 CO2 Incubator. Both of these pieces of equipment will support the research group?s ongoing work looking for potential cancer vaccines, engineering T-cells against cancer and studying T-cells from patients who have undergone successful cancer immunotherapy.

Leica M60 Stereomicroscope

An important part of our work revolves around visualizing the molecular interactions that take place between T-cell receptors and molecular parts of cells infected with viruses or that have become cancerous. It is impossible to ?see? molecules using light, so we use high energy X-rays and a technique called X-ray crystallography. This requires that we crystallize the molecules we want to look at and transport them to Diamond Light Source (the UK's synchrotron facility) where they are placed in a high energy X-ray beam. The way the atoms in the molecules scatter these X-rays can be used to build up an atomic structure of the molecule. We have produced molecular structures of more than 90 immune molecules and this structural analysis has given us an insight into T-cell function, viral escape mechanisms, mechanisms of autoimmunity, information on potential vaccines and on how the immune system can distinguish healthy cells from cancer cells.

The new microscope will streamline the process of crystal-harvesting. The speed of harvesting is known to impinge on the final resolution of the molecular image that can be obtained. As things stand, most of the crystals we harvest do not produce useful data. This microscope could reduce this failure rate.

Thermo BB15 CO2 Incubator, including a stacking stand

Growing immune cells requires that we mimic the situation inside the body in terms of oxygen:carbon dioxide ration and temperature. A new CO2 Incubator will provide increased capacity in the tissue culture laboratory. Unfortunately, a recent power cut resulted in the malfunction of an old but essential incubator. We do not have the funds to replace this incubator at this time due to the unforeseen nature of the breakdown. The new incubator will allow us to continue working on all our projects to the same capacity without risking adverse events by overloading the existing infrastructure. The stacking stand we will be able to increase the capacity without increasing the footprint of the equipment in the limited space we have available for tissue culture.


Cancer Research & Genetics UK are in negotiations to buy £10k of equipment for the new Liverpool Cancer Hospital / Clatterbridge Cancer Centre.


Video of Dr Helen Pearson explaining the impact of the vibratome, funded by Cancer Research and Genetics UK, which sits in the Marcia Phillips Tissue Culture Suite in the European Cancer Stem Cell Research Institute.


Cancer Research & Genetics UK donated £10,000 to the Manchester Cancer Research Centre who work closely with the Christie NHS Foundation Trust, the largest cancer hospital in Europe.

To read our latest communications with the university please click here and here.

To find out more about the great work the university does and how we support them click here.


Cancer Research & Genetics UK are currently in negotiations with Manchester University to donate a further £10,000 to purchase equipment for cancer research. More details to follow...


One year ago Cancer Research & Genetics UK donated £10,000 to Manchester University to purchase a gentleMACS dissociator. The University has recently got back to us with an update on the progress made in prostate cancer care and research.

To read what they sent us please click here.


This important donation from Cancer Research & Genetics UK will help support our preclinical studies, investigating how we can improve the efficacy of targeted therapeutic agents to treat prostate cancer and advance our understanding of how this disease develops therapeutic resistance. This donation will facilitate the purchase of a tissue slicer, that can be used to generate thin sections of prostate cancer specimens for culture in plastic dishes. By taking this approach, we can rapidly determine the initial response of prostate tumours to therapeutic interventions ex vivo, yet advantageously in the context of an intact tumour microenvironment. By establishing the therapeutic responses of prostate cancer cells and their surrounding microenvironment to new therapeutic strategies, we hope to preclinically test/validate new therapeutic approaches to inform the design of future clinical trials that can benefit patients with prostate cancer.

- Dr Helen Pearson, Cardiff University


Support from Cancer Research & Genetics UK in 2018 has now been used to purchase an embedding machine for the immunohistochemistry facility, which is currently in development.

The Institute would like to thank Cancer Research Genetics UK for their donations in recent years.

A donation in 2019 would be used to purchase two items of equipment for a new gene editing (CRISPR-Cas9-rAAV) facility:

Gene (and Genome) editing is revolutionising molecular biology and translational research. For the first time, we have the ability to carry out wide-ranging genetic manipulation in mammalian systems. This gives us the ability to understand how genes function and interact in models of human disease with the potential to transform how we understand and treat patients. The best way to investigate the function of a gene is to (1) knockdown/overexpress it in cells or (2) modify its DNA sequence in the genome of a cell line to imitate the effect of known mutations associated with the disease.


Cardiff University have used our donation towards purchasing a Vibratome. Which is a Leica microtome that enables researchers to section up tumour samples for culturing slices of tissue in plastic dishes. Dr Helen Pearson has a number of prostate cancer tumour models she would like to culture using this technique, as it enables us to measure short term drug responses ex vivo, with an intact microenvironment.


Cancer Research and Genetics UK's donation will fund the purchase of equipment for an immunohistochemistry facility within the Department of Molecular and Clinical Cancer Medicine at the University of Liverpool.

This new facility will also be available to other departments within the Institute of Translational Medicine at the University, where the Department of Molecular and Clinical Cancer Medicine is a key component of the North West Cancer Research Centre. Research areas include pancreas cancer research, ocular oncology, lung cancer, head and neck cancer research, haemato-oncology, academic medical oncology and early drug development, clinical trials and palliative care.

More information - click here.


Cancer Research & Genetics UK are donating £10,000 to purchase equipment for Dr Helen Pearsons Research into prostate cancer genetics and treatments at Cardiff Universitiy European Cancer Stem Cell Research.

New research has uncovered insights into the mechanisms that underlie prostate cancer, providing potential targets for new cancer therapies. There is more information online here and you can watch a video of Dr Helen Pearson explaining the research here.

Our donation will help support the University's research into understanding how genetic alterations contribute to prostate cancer growth and will gain further insight into how prostate cancer develops resistance to current treatments. This contribution will enable the University to purchase an essential piece of equipment to rapidly and efficiently homogenise prostate tissue samples, which is necessary for isolating genomic material for analysis. Once isolated, we can measure if genes are up regulated or down regulated in response to a genetic alteration or treatment. By identifying changes in the genome of prostate tumours, we hope to discover new therapeutic strategies and biomarkers that will ultimately improve our management of patients with prostate cancer.


Cancer Research & Genetics UK are donating £10,000 to Glasgow University in Scotland to buy a Luminescence Plate Reader - for the Institute of Cancer Sciences department. Dr Fiona Thomson has provided some information about this equipment and how the donation will help:

"Our research aims to develop novel anti-cancer agents through clinical trials in patients and this donation will help support our efforts to develop better cancer treatments. Specifically, the funds will contribute towards the purchase of a piece of equipment, called a luminescence plate reader, that will be used to help measure the effectiveness of novel drugs which are being testing in pancreatic cancer patients. We are hoping that this new drug, when used alongside chemotherapy and radiotherapy, will improve the care and treatment of pancreatic cancer patients."


Cancer Research & Genetics UK have donated £10,000 to purchase Imaging equipment in the X- Clarity Tissue Clearing System at Cardiff University. The research is led by Professor Matt Smalley at the European Cancer Stem Cell Research based at the University.

X-CLARITY Tissue Clearing system. Revealing tumour composition, architecture and underlying mechanisms in 3D

Tumours are heterogeneous complex environments composed of multiple cell types and matrix proteins. How cells interact and organize within a tumour often hint at the underlying biology that governs tumour development and malignancy. Equally, by monitoring expression levels, activity or localisation of specific proteins within cells also informs on mechanisms and may identify new therapeutic targets. Traditionally, we have relied on immunofluorescence methods to label cells within slices of fixed tissue and then retrospectively build 3D maps of the tissue using specialised confocal microscopy and image analysis tools. This traditional approach requires specialised training and expertise, and is also time consuming.

Recent advances in tissue imaging have led to the development of the CLARITY method (Clear Lipid-exchanged Acrylamide-hybridised Rigid Imaging/Immunostaining/In situ-hybridisation-compatible Tissue-hYdrogel). This method clears or removes masking lipids from whole tissues to make them transparent, exposing the remaining protein and DNA in cells. Because the tissue is fixed in a hydrogel scaffold, this method allows us to examine proteins and therefore cellular structures within preserved 3D tissue architecture. We propose to purchase the X-CLARITY tissue clearing system from Labtech. This equipment provides an all-in-one automated, rapid and efficient tissue clearing protocol, without exposing the user to toxic chemicals or extended incubation steps. Therefore, the protocol is standardised, which saves time and increases robustness. The stained tissue is then imaged in a specialised microscope called a Light sheet (Selective Plane Illumination Microscopy; SPIM, in house at the School of Biosciences). Light sheet microscopy is a time efficient way to rapidly image 3D systems. Together, this approach will allow us to build 3D maps of increasing complexity that reflect the subcellular and cellular networks of a tumour. The CLARITY method can be applied to any solid tumour, including pancreas, breast, brain and bone. This will give us a better understanding of the biology underlying tumour development and help us to identify rare metastatic lesions in secondary organs.


Cancer Research & Genetics UK are in negotiations to buy Cancer Research Equipment for Glasgow University in Scotland.


Cancer Research & Genetics Uk have donated £10,000 to purchase equipment for Proffesors Andrew Pettit and Sarah Coupland and Mark Boyds research at Liverpool University. The Researches are based in the Universities Department of Molecular and Clinical and Cancer Medicine which specialises in Blood, Eyes and Head and Neck Cancers respectively.

The Department of Molecular and Clinical Cancer Medicine provides a vibrant home to approximately 200 staff including 30 principle investigators who collectively lead a comprehensive programme of basic, translational and clinical cancer research. Clinical focus areas include pancreas cancer, ocular oncology, lung cancer, head and neck cancer, hepatobiliary cancer, haematological oncology, urological cancer and breast cancer while areas of particular scientific strength include DNA repair, p53 biology and tumour microenvironment.


Cancer Research Genetics UK are donating £10,000 to Dr Esther Baena and her research into Prostate Oncobiology at Manchester University. The University is linked closely to Christie Hospital Manchester.

The goal of the Prostate Oncobiology group is to advance our understanding of cancer signalling pathways and to identify tumour-initiating cells. A central challenge in cancer research is the identification of cancer patients whose disease will eventually progress to the lethal stage. Due to the cytogenetic complexity of epithelial cancers, little is known about their origins and the steps required for progression from local to advanced disease.

The donation will enable them to purchase cancer genetic research eguipment. The machine will sort through the tissue samples they get from the hospital much faster than can be done by a human. This will mean they get more cells, of better quality and greater viability for growing in the lab – all aimed at ultimately genetically identifying those patients whose prostate cancer is showing most worry genetic traits of growing really quickly.

Manchester University is linked to the Christie Hospital Manchester which is Europes largest single site cancer centre.


Cancer Research Genetics UK have donated £10,000 to purchase equipment for Prof. Awen Gallimore’s lab. to conduct research into cancer immunology at Cardiff University.

The donation will be used to fund an image analysis station for the research team which will allow the researchers to perform far better analysis of cancer sections stained by immunofluorescence and immunohistochemistry. A station comprises a package of image analysis software and a high spec computer to run it on.

IMARIS Imaging System - Identifying Bottlenecks to Successful Immunotherapy

Recent advances indicate that it is possible to use the power of the immune system to fight cancer. Whilst there have been notable successes in the treatment of melanoma there remain significant bottlenecks to success in other cancers. This may be due to the nature of the environment in which the cancer is growing. In the case of some cancers, the nature of the environment is such that it allows immune cells to enter unimpeded whilst in other cases, components of the cancer environment prevent effective entry of immune cells. This is a significant problem as if the immune cells cannot enter a cancer, they will fail to kill it.

One key objective of our research is to identify components of the environment that allow or prevent entry of immune cells. To achieve this, we analyse sections of tumour cells in detail using fluorescently- or chemically-labelled tags that allow us to formulate a map of the cancer environment which takes into account 1) the cancer cells, 2) other cell types present which render cancer cells more or less aggressive, 3) cells of the immune system and 4) blood vessels. Visualisation of the component parts is carried out using microscopy and images are recorded for further analysis. The IMARIS software system will significantly improve our ability to perform in-depth analysis of these stained tissues. It will allow us to trace individual cells as well as examine their spatial and functional relationships with other cells. The software is also quantitative and will allow us to determine the frequencies of particular cell types or e.g. the size of tumour blood vessels. Moreover, we will be able to perform this type of analysis using thick pieces of tissues thereby improving significantly on the quality and quantity of information to be gained.

The overall objective of this work is to identify pathways which can be targeted by pharmacological and/or biological therapies and which can be used to maximise the power of the immune system for killing cancer.

More information about Awen's work in cancer immunology can be found online here - http://cancerimmunology.co.uk/


Cancer Research Genetics UK have donated £10,000 to Dr Mathew Smalley at Cardiff University and European Cancer Stem Cell Research Institute for new equipment.

The ECSCRI team will purchase equipment for the Marcia Phillips Tissue Culture Suite which will allow them to perform low oxygen cell cultures. Low oxygen levels are often found at the centre of solid tumours, and cancer cells (and normal cells) behave very differently in these conditions. The incubator will allow researchers to mimic these conditions within tumours to determine cancer stem cell behaviour and responses to therapies. In addition they will also purchase a “GentleMACS Disruptor” which allows for automated separation of solid tumour samples into their individual cancer cells without harming the cells in the process.

More research news from Cardiff University.


Cancer Research Genetics UK have donated £10,000 to Professor Ros Eeles Prostate Cancer Genetic Research at the Institute of Cancer Research in London.

ICR logo

Professor Ros Eeles is a leader in prostate cancer genetics at the ICR. She is a scientist as well as a clinician and is looking into new types of testing procedures for early stage prostate cancer.


Cancer Research Genetics UK have donated £10,000 to Professor Ros Eeles Prostate Cancer Genetic Research at the Institute of Cancer Research in London.

Professor Ros Eeles is a leader in prostate cancer genetics at the ICR. She is a scientist as well as a clinician and has discovered 85 of the known 112 common variants associated with prostate cancer predisposition.

She is also is looking into young onset prostate cancer. She has a collection UK-wide of 10,000 young onset prostate cancer case samples (diagnosed at 60 years or less). She is looking to identify genetic alterations which are particularly found in young onset disease to enable ICR to use these in targeted screening and treatment trials.

To learn more visit the IRC Facebook page - click here.


Cancer Research Genetics UK have donated £10,000 to Prof Alan Clark's cancer stem cell research at Cardiff University.

To see more information on Prof Clark's work - click here.

Professor Clarke's main interest is in the molecular basis of cancer, particularly in the very early stages when cells initially diverge from normality.

Professor Clarke's group will work with the Research Institute on the genetic origins of cancer stem cells, and the susceptibility of these cells to existing and new therapies.


Cancer Research Genetics UK have donated £10,000 to Dr Marco Gerlinger’s research. His work involves developing novel strategies to overcome drug resistance in advanced Bowel cancer. He is based at the Institute of Cancer Research London which is linked to the Royal Marsden Hospital.

To see more information on Dr Gerlinger's work - click here.

He is developing novel strategies to overcome drug resistance in advanced bowel cancer.


ICR logo

Cancer Research and Genetics UK have just donated £10,000 to The Institute of Cancer Research (ICR) to help with Professor Richard Houlston's work in cancer genetics.

The ICR is in London and it has working links for cancer genetic research with the Royal Marsden Hospital, London.

The ICR has some of the world’s leading scientists identifying the genes that predispose us to cancer.


To read more about the centre's work click here.


We have donated £10,000 to the work of Professor Philip Rudland at Liverpool University who is looking at the identification of genetic changes that promote the spread of cancer in the body.

Aim of Project
We need to know why these metastasis-inducing genes are preferentially turned on in some patients contributing to their early death, but not in others enabling them to survive much longer.

To read the full application please click here.

The University of Liverpool would like to thank Cancer Research Genetics UK for supporting their work on cancer research.





Cancer Research Genetic's have made a donation of £10,000 to the work of Professor Alan Clark and the European Cancer Stem Cell Research Institute, based at Cardiff University.

Professor Clark feels that this money would bring significant benefit to ECSCRI and the research that is undertaken therein. At the moment the Institute is looking to purchase the following hi-tec equipment:


Cancer Research and Genetics UK are currently regularly donating to Professor Alan Clarke and his European Cancer Stem Cell Research Institute (ECSCRI) based at Cardiff University.


Doctors (GPs) miss one in three cancer cases - click here.


Cancer Research and Genetics UK are currently donating regularly to Professor Julian Sampson's Cancer Genetic Research work at Cardiff University.


Cancer Research and Genetics UK are working in collaboration with Recycle Proline LTD a company based in Liverpool who are donating funds regularly to the charity which is directed into Cancer Research and Genetics and to the charities objectives and aims.

Total Health

Genetic link to childhood cancer - click here.

ICR news

Bowel cancer gene found - click here.

NICE news

Thoracoscopic excision of mediastinal parathyroid tumours - click here.

ECPC news

ECPC logo

We have exciting news from the European Parliament. The Committee on Environment/Public Health has tabled a draft Resolution on “Combating cancer in the enlarged European Union”. The draft Resolution and Oral question is now posted on the European Parliament website, eventually in all official EU languages. The Resolution is expected to be adopted by the European Parliament plenary in the week of 18 February or 10 March 2008. In our view this will make an excellent contribution to the Slovenian Presidency cancer agenda. Please note that the Resolution once adopted will be forwarded to your national parliament. We hope this provides you with opportunities to make the case for improved cancer control in your country.

Oral question -  click here.

Draft Motion for Resolution - click here.

Home|Support|Specific Cancers|Genetics|Research|News|Links|Contact Us